Cryogenic OGS Limited Reports No Deviation in IPO Fund Utilization for FY26
Cryogenic OGS Limited has filed its mandatory fund utilization statement for the half-year ended March 31, 2026, confirming no deviations in the use of ₹17.76 crores raised through its IPO on July 10, 2025. The company has systematically deployed funds across working capital requirements (₹240.12 lakhs utilized from ₹1150.00 lakhs allocated), general corporate purposes (₹284.31 lakhs from ₹396.47 lakhs), and issue expenses (₹228.29 lakhs from ₹230.13 lakhs). The statement, approved by the board and audit committee on April 30, 2026, demonstrates compliance with SEBI regulations and transparent fund management practices.

*this image is generated using AI for illustrative purposes only.
Cryogenic OGS Limited has submitted its compliance statement to BSE Limited regarding the utilization of funds raised through its initial public offering, confirming no deviations from the approved allocation for the half-year ended March 31, 2026. The statement, filed under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, was reviewed and approved by the company's audit committee and board of directors on April 30, 2026.
IPO Fund Details and Allocation
The company raised ₹17.76 crores through its initial public offer completed on July 10, 2025. The funds were allocated across three specific objectives as outlined in the original prospectus.
| Parameter | Details |
|---|---|
| Mode of Fund Raising | Initial Public Offer |
| Date of Fund Raising | July 10, 2025 |
| Total Amount Raised | ₹17.76 Crores |
| Reporting Period | Half-year ended March 31, 2026 |
| Deviation Status | No |
Fund Utilization Breakdown
The detailed utilization of IPO proceeds shows systematic deployment across the three approved categories. The company has utilized funds progressively towards its stated objectives without any modifications to the original allocation.
| Object of Issue | Original Allocation (₹ Lakhs) | Funds Utilized (₹ Lakhs) | Status |
|---|---|---|---|
| Working Capital Requirements | 1150.00 | 240.12 | On Track |
| General Corporate Purpose | 396.47 | 284.31 | On Track |
| Issue Related Expenses | 230.13 | 228.29 | Nearly Complete |
Compliance and Oversight
The fund utilization statement confirms that no monitoring agency oversight is required for this fundraising. Both the audit committee and external auditors have provided no adverse comments on the fund deployment strategy. The company has maintained transparency by making the statement available on its official website at cryogenicogs.com.
Corporate Governance
The statement was signed by Managing Director Nilesh Patel (DIN: 01368574) and Company Secretary & Compliance Officer Rashmi Kamlesh Otavani, demonstrating proper corporate governance protocols. The document confirms that no shareholder approval was required for any changes in fund utilization as no deviations occurred from the original objects of the issue.
Historical Stock Returns for Cryogenic Ogs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -8.18% | +30.29% | +41.22% | +1.56% | +143.17% | +143.17% |
What specific business expansion plans does Cryogenic OGS have for the remaining ₹910 lakhs in working capital funds over the next reporting periods?
How will the company's financial performance in FY2027 be impacted by the strategic deployment of these IPO proceeds?
What market opportunities in the cryogenic equipment sector is Cryogenic OGS positioning itself to capture with this capital infusion?


































